Patents Examined by Ponnathapu Achutamurthy
  • Nucleic acid sequences encoding alkaline alpha-amylases
    Patent number: 6623948
    Abstract: The present invention relates to isolated nucleic acid sequences encoding polypeptides having alpha-amylase activity [E.C. 3.2.1.1], which may be derived from Bacillus. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing and using the polypeptides.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: September 23, 2003
    Assignee: Novozymes A/S
    Inventors: Helle Outtrup, Lisbeth Hedegaard Hoeck, Bjarne Ronfeldt Nielsen, Torben Vedel Borchert, Vibeke Skovgaard Nielsen, Henrik Bisgård-Frantzen, Allan Svendsen, Carsten Andersen
  • Modified enzymes having polymer conjugates
    Patent number: 6623950
    Abstract: The present invention relates to polypeptide-polymer conjugates having added and/or removed one or more attachment groups for coupling polymeric molecules on the surface of the polypeptide structure, a method for preparing polypeptide-polymer conjugates of the invention, the use of said conjugates for reducing the immunogenicity and allergenicity and compositions comprising said conjugate.
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: September 23, 2003
    Assignee: Novozymes A/S
    Inventors: Claus von der Osten, Arne Agerlin Olsen, Erwin Ludo Roggen
  • Human cathepsin
    Patent number: 6620606
    Abstract: The invention provides a new human cathepsin (LCAP) and polynucleotides which identify and encode LCAP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of LCAP.
    Type: Grant
    Filed: March 7, 2000
    Date of Patent: September 16, 2003
    Assignee: Incyte Corporation
    Inventors: Olga Bandman, Karl J. Guegler, Neil C. Corley, Purvi Shah
  • DNA molecules encoding fibrinolytically active polypeptide
    Patent number: 6617145
    Abstract: A fibrinolytically active metalloproteinase polypeptide (called “novel acting thrombolytic”) which is useful for blood clot lysis in vivo and methods and materials for its production by recombinant expression are described.
    Type: Grant
    Filed: May 1, 2001
    Date of Patent: September 9, 2003
    Assignee: Amgen Inc
    Inventors: Thomas C. Boone, Huimin Li, Michael B. Mann
  • Isolated human enzyme, nucleic acid molecules encoding human enzyme, and uses thereof
    Patent number: 6613554
    Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the enzyme peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the enzyme peptides, and methods of identifying modulators of the enzyme peptides.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: September 2, 2003
    Assignee: Applera Corporation
    Inventors: Ming-Hui Wei, Chunhua Yan, Valentina DiFrancesco, Ellen M. Beasley
  • 32142, 21481, 25964, 21686, novel human dehydrogenase molecules and uses therefor
    Patent number: 6613555
    Abstract: The invention provides isolated nucleic acids molecules, designated DHDR nucleic acid molecules, which encode novel DHDR-related dehydrogenase molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing DHDR nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DHDR gene has been introduced or disrupted. The invention still further provides isolated DHDR proteins, fusion proteins, antigenic peptides and anti-DHDR antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: September 2, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel Meyers, William James Cook, Mark Williamson, Laura A. Rudolph-Owen
  • Cloned genes encoding reverse transcriptase lacking RNase H activity
    Patent number: 6610522
    Abstract: The invention relates to a gene which encodes reverse transcriptase having DNA polymerase activity and substantially no RNase H activity. The invention also relates to vectors containing the gene and hosts transformed with the vectors of the invention. The invention also relates to a method of producing reverse transcriptase having DNA polymerase activity and substantially no RNase H activity by expressing the reverse transcriptase genes of the present invention in a host. The invention also relates to a method of producing cDNA from mRNA using the reverse transcriptase of the invention. The invention also relates to a kit for the preparation of cDNA from mRNA comprising the reverse transcriptase of the invention.
    Type: Grant
    Filed: December 24, 1998
    Date of Patent: August 26, 2003
    Assignee: Invitrogen Corporation
    Inventors: Michael Leslie Kotewicz, Gary Floyd Gerard
  • Protease variants and compositions
    Patent number: 6605458
    Abstract: A protease subtilase enzyme, characterized by an insertion in at least one active site loop. The enzymes exhibit improved wash performance in a detergent in comparison to its parent enzyme if it is a subtilase variant.
    Type: Grant
    Filed: November 19, 1998
    Date of Patent: August 12, 2003
    Assignee: Novozymes A/S
    Inventors: Peter Kamp Hansen, Peter Bauditz, Frank Mikkelsen
  • Nucleic acids encoding IKR-2, a protein kinase related to the I kappa B kinases
    Patent number: 6605456
    Abstract: The invention is directed to purified and isolated kappa B kinase-related kinases 1 and 2 (IKR-1 and IKR-2) polypeptides and fragments thereof, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Grant
    Filed: June 9, 2000
    Date of Patent: August 12, 2003
    Assignee: Immunex Corporation
    Inventors: Timothy A. Bird, G. Duke Virca
  • Human elastase IV
    Patent number: 6602984
    Abstract: Human elastase IV polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptide by recombinant techniques and utilizing such polypeptide for therapeutic purposes, for example, restoration of elasticity of arterial walls, improvement of serum lipid abnormality and improvement of serum lipoprotein metabolism are disclosed. Also disclosed are antagonist/inhibitors against such polypeptides and their use in treating inflammation, arthritis, e.g. rheumatoid arthritis and osteoarthritis, septic shock, pancreatitis and limiting tissue damage in ulceration. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.
    Type: Grant
    Filed: July 11, 2000
    Date of Patent: August 5, 2003
    Assignee: Human Genome Sciences, Inc.
    Inventors: John M. Greene, Mark D. Adams
  • Synthetic peptides from streptococcal M protein and vaccines prepared therefrom
    Patent number: 6602507
    Abstract: Synthetic polypeptides from the conserved exposed region of streptococcal M protein are useful to prepare vaccines for oral or intranasal administration which will protect against streptococcal infection.
    Type: Grant
    Filed: January 6, 1995
    Date of Patent: August 5, 2003
    Assignee: The Rockefeller University
    Inventor: Vincent A. Fischetti
  • Subtilisin 309 variants having decreased adsorption and increased hydrolysis
    Patent number: 6599730
    Abstract: The present invention relates to subtilisin 309 variants having a modified amino acid sequence of wild-type subtilisin 309 amino acid sequence, the wild-type amino acid sequence comprising a first loop region, a second loop region, a third loop region, a fourth loop region, a fifth loop region and a sixth loop region; wherein the modified amino acid sequence comprises different amino acids than that occurring in wild-type subtilisin 309 (i.e., substitution) at specifically identified positions in one or more of the loop regions whereby the subtilisin 309 variant has decreased adsorption to, and increased hydrolysis of, an insoluble substrate as compared to the wild-type subtilisin 309. The present invention also relates to DNA sequence encoding such subtilisin 309 variants. The present invention also relates to compositions comprising such subtilisin 309 variants for cleaning a variety of surfaces.
    Type: Grant
    Filed: March 7, 1995
    Date of Patent: July 29, 2003
    Assignee: Procter & Gamble Company
    Inventors: Philip Frederick Brode, III, Bobby Lee Barnett, Donn Nelton Rubingh, Chanchal Kamur Ghosh
  • Composition and methods relating to SENP 1- a sentrin-specific protease
    Patent number: 6596527
    Abstract: The invention relates to a novel protease, called SENP1, which is active against sentrin-modified proteins in vivo. The invention more specifically relates to the genomic and amino acid sequences for SENP1, compositions related to and based on these sequences, and methods of using these sequences and compositions.
    Type: Grant
    Filed: July 31, 2000
    Date of Patent: July 22, 2003
    Assignee: Board of Regents, The University of Texas Sytem
    Inventors: Edward T. H. Yeh, Limin Gong
  • Cloned genes encoding reverse transcriptase lacking RNase H activity
    Patent number: 6589768
    Abstract: The invention relates to a gene which encodes reverse transcriptase having DNA polymerase activity and substantially no RNase H activity. The invention also relates to vectors containing the gene and hosts transformed with the vectors of the invention. The invention also relates to a method of producing reverse transcriptase having DNA polymerase activity and substantially no RNase H activity by expressing the reverse transcriptase genes of the present invention in a host. The invention also relates to a method of producing cDNA from mRNA using the reverse transcriptase of the invention. The invention also relates to a kit for the preparation of cDNA from mRNA comprising the reverse transcriptase of the invention.
    Type: Grant
    Filed: December 24, 1998
    Date of Patent: July 8, 2003
    Assignee: Invitrogen Corporation
    Inventors: Michael Leslie Kotewicz, Gary Floyd Gerard
  • Acidophile archaeal organism
    Patent number: 6589772
    Abstract: A new species of acidophilic microorganism has bee isolated from a acid mine drainage site. The organism is an archaea here given the tentative species designation Ferroplasma acidarmanus and the strain designation fer1. This organism is tolerant of extraordinary conditions of low pH and high metal concentrations.
    Type: Grant
    Filed: February 29, 2000
    Date of Patent: July 8, 2003
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Jillian F. Banfield, Katrina J. Edwards, Philip L. Bond, Thomas M. Gihring
  • Keratinocyte derived protease
    Patent number: 6589770
    Abstract: Disclosed is an isolated polypeptide comprising an amino acid sequence substantially as shown in SEQ ID NO:2, or substantially similar to an amino acid sequence encoded by a nucleotide sequence in a plasmid having all the identifying characteristics of Deposit No. FERM BP-6129. Also disclosed is an isolated polynucleotide substantially as shown in SEQ ID NO:1, or substantially similar to a nucleotide sequence contained in a plasmid having all of the identifying characteristics of Deposit No. FERM BP-6129. Further disclosed is an expression system comprising the above polynucleotide. Further disclosed is a composition comprising the above polypeptide.
    Type: Grant
    Filed: April 3, 2000
    Date of Patent: July 8, 2003
    Assignee: The Procter & Gamble Company
    Inventors: Haruo Kitado, Akikazu Yoshikawa, Tomoko Zaiki
  • Subtilisin variants multiply-substituted subtilising variants having a substitution at position 76
    Patent number: 6586221
    Abstract: Novel carbonyl hydrolase variants derived from the DNA sequences of naturally-occurring or recombinant non-human carbonyl hydrolases are disclosed. The variant carbonyl hydrolases, in general, are obtained by in vitro modification of a precursor DNA sequence encoding the naturally-occurring or recombinant carbonyl hydrolase to generate the substitution of a plurality of amino acid residues in the amino acid sequence of a precursor carbonyl hydrolase. Such variant carbonyl hydrolases have properties which are different from those of the precursor hydrolase, such as altered proteolytic activity, altered stability, etc.
    Type: Grant
    Filed: October 13, 1994
    Date of Patent: July 1, 2003
    Assignee: Genencor International, Inc.
    Inventors: Thomas P. Graycar, Richard R. Bott, Lori J. Wilson
  • Recombinant &agr;-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
    Patent number: 6585971
    Abstract: The present invention provides a recombinant human &agr;-L-iduronidase and biologically active fragments and mutants thereof, large scale methods to produce and purify commercial grade recombinant human &agr;-L-iduronidase enzyme as well as methods to treat certain genetic disorders including &agr;-L-iduronidase deficiency and mucopolysaccharidosis I (MPS 1).
    Type: Grant
    Filed: November 9, 2000
    Date of Patent: July 1, 2003
    Assignee: Harbor-UCLA Research and Education Institute
    Inventor: Emil D. Kakkis
  • Deregulation of glutamine PRPP amidotransferase activity
    Patent number: 6586216
    Abstract: The present invention is directed to a modified amidotransferase. The amino acid sequence of the modified amidotransferase differs from the amino acid sequence of a native E. coli glutamine PRPP amidotransferase in that one or more amino acid residues of the modified amidotransferase are substituted at positions equivalent to amino acid positions in Bacillus amidotransferase selected from the group consisting of 282, 283, 307, and 347 of SEQ ID NO:1, wherein the modified amidotransferase is less sensitive to end-product inhibition than is the native E. coli glutamine PRPP amidotransferase.
    Type: Grant
    Filed: March 13, 2001
    Date of Patent: July 1, 2003
    Assignees: Purdue Research Foundation, The Board of Trustees of the University of Illinois
    Inventors: Howard Zalkin, Janet L. Smith, Robert L. Switzer
  • Subtilisin protease variants having amino acid deletions and substitutions in defined epitope regions
    Patent number: 6586224
    Abstract: The present invention relates to variants of subtilisin-like proteases having decreased immunogenicity relative to their corresponding wild-type proteases. The present invention further relates to such variants additionally having one or more amino acid substitutions in one or more epitope regions or additionally having one or more stabilizing substitutions. The invention further relates to mutant genes encoding such variants and cleaning and personal care compositions comprising such variants.
    Type: Grant
    Filed: July 18, 2000
    Date of Patent: July 1, 2003
    Assignee: The Procter & Gamble Company
    Inventors: Donn Nelton Rubingh, Elizabeth Ellen Sikorski